- Home
- ZDAI vs NXTC Comparison
ZDAI vs NXTC Comparison
Compare ZDAI & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZDAI
- NXTC
- Stock Information
- Founded
- ZDAI 2022
- NXTC 2015
- Country
- ZDAI Hong Kong
- NXTC United States
- Employees
- ZDAI N/A
- NXTC N/A
- Industry
- ZDAI General Bldg Contractors - Nonresidential Bldgs
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- ZDAI Consumer Discretionary
- NXTC Health Care
- Exchange
- ZDAI Nasdaq
- NXTC Nasdaq
- Market Cap
- ZDAI 13.5M
- NXTC 12.8M
- IPO Year
- ZDAI 2024
- NXTC 2019
- Fundamental
- Price
- ZDAI $0.53
- NXTC $5.12
- Analyst Decision
- ZDAI
- NXTC Strong Buy
- Analyst Count
- ZDAI 0
- NXTC 2
- Target Price
- ZDAI N/A
- NXTC $25.50
- AVG Volume (30 Days)
- ZDAI 69.7K
- NXTC 318.4K
- Earning Date
- ZDAI 08-29-2025
- NXTC 08-07-2025
- Dividend Yield
- ZDAI N/A
- NXTC N/A
- EPS Growth
- ZDAI N/A
- NXTC N/A
- EPS
- ZDAI N/A
- NXTC N/A
- Revenue
- ZDAI $19,275,673.00
- NXTC N/A
- Revenue This Year
- ZDAI N/A
- NXTC N/A
- Revenue Next Year
- ZDAI N/A
- NXTC N/A
- P/E Ratio
- ZDAI N/A
- NXTC N/A
- Revenue Growth
- ZDAI 56.11
- NXTC N/A
- 52 Week Low
- ZDAI $0.37
- NXTC $2.69
- 52 Week High
- ZDAI $107.36
- NXTC $19.80
- Technical
- Relative Strength Index (RSI)
- ZDAI N/A
- NXTC 48.99
- Support Level
- ZDAI N/A
- NXTC $4.75
- Resistance Level
- ZDAI N/A
- NXTC $5.23
- Average True Range (ATR)
- ZDAI 0.00
- NXTC 0.31
- MACD
- ZDAI 0.00
- NXTC 0.02
- Stochastic Oscillator
- ZDAI 0.00
- NXTC 53.28
About ZDAI Primega Group Holdings Limited Ordinary Shares
Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.